{"id":59343,"date":"2026-03-12T13:30:54","date_gmt":"2026-03-12T05:30:54","guid":{"rendered":"https:\/\/flcube.com\/?p=59343"},"modified":"2026-03-12T13:30:55","modified_gmt":"2026-03-12T05:30:55","slug":"changchun-genesciences-gensci128-wins-fda-orphan-drug-designation-tp53-y220c-reactivator-targets-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59343","title":{"rendered":"Changchun GeneScience&#8217;s GenSci128 Wins FDA Orphan Drug Designation \u2013 TP53 Y220C Reactivator Targets Pancreatic Cancer"},"content":{"rendered":"\n<p><strong>Changchun GeneScience Pharmaceutical Inc.<\/strong> announced that <strong>GenSci128 tablets<\/strong>, its <strong>independently developed selective TP53 Y220C mutation reactivator<\/strong>, has received <strong>U.S. FDA Orphan Drug Designation (ODD)<\/strong> for the treatment of <strong>pancreatic cancer<\/strong>. The <strong>Class 1 innovative chemical drug<\/strong> in China, which <strong>restores normal conformation and transcriptional activity<\/strong> of the mutant TP53 protein, holds <strong>IND approvals from both FDA and NMPA<\/strong> for <strong>locally advanced or metastatic solid tumors<\/strong> harboring the <strong>TP53 Y220C mutation<\/strong>, including <strong>pancreatic, ovarian, breast, and colorectal cancers<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Orphan Drug Designation (ODD)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>GenSci128 tablets<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Selective small-molecule TP53 Y220C mutation reactivator \u2013 Class 1 innovative chemical drug (China)<\/td><\/tr><tr><td><strong>Indication (ODD)<\/strong><\/td><td>Pancreatic cancer<\/td><\/tr><tr><td><strong>Broader Indications<\/strong><\/td><td>TP53 Y220C-mutant locally advanced\/metastatic solid tumors (pancreatic, ovarian, breast, colorectal)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Changchun GeneScience Pharmaceutical Inc. \u2013 independently developed<\/td><\/tr><tr><td><strong>U.S. Regulatory Pathway<\/strong><\/td><td>505(b)(1) \u2013 new molecular entity<\/td><\/tr><tr><td><strong>Prior Approvals<\/strong><\/td><td>\u2022 FDA IND approved<br>\u2022 NMPA China clinical trial approved<\/td><\/tr><tr><td><strong>Designation Date<\/strong><\/td><td>11\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>GenSci128 Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td>TP53 Y220C mutant protein (structural mutation in DNA-binding domain)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>\u2022 Selective binding to Y220C mutant pocket<br>\u2022 Restores normal protein conformation<br>\u2022 Increases mutant protein stability<br>\u2022 Reactivates transcriptional activity<br>\u2022 Restores tumor-suppressive functions<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Small-molecule mutant p53 reactivator (first-in-class potential)<\/td><\/tr><tr><td><strong>Preclinical Profile<\/strong><\/td><td>Favorable efficacy and safety demonstrated<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Oral tablets<\/td><\/tr><tr><td><strong>Innovation Status<\/strong><\/td><td>Class 1 innovative chemical drug (China); 505(b)(1) pathway (U.S.)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Scientific Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TP53 Y220C:<\/strong> Structural mutation creates druggable pocket; ~1% of all cancers; enriched in pancreatic (2-3%), ovarian, breast, colorectal<\/li>\n\n\n\n<li><strong>Loss of Function:<\/strong> Mutant p53 loses tumor suppression; gain-of-function oncogenic properties<\/li>\n\n\n\n<li><strong>Reactivation Strategy:<\/strong> Small molecule binding restores wild-type conformation \u2192 transcriptional activation of p53 target genes (p21, PUMA, Bax) \u2192 cell cycle arrest\/apoptosis<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-opportunity\">Strategic Context &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Pancreatic Cancer Burden<\/strong><\/td><td>60,000+ U.S. cases annually; 5-year survival &lt;10%; TP53 mutations in 50-75% (Y220C subset addressable)<\/td><\/tr><tr><td><strong>TP53 Drugability<\/strong><\/td><td>Historically &#8220;undruggable&#8221; target; GenSci128 first-in-class reactivation approach validates new paradigm<\/td><\/tr><tr><td><strong>ODD Benefits<\/strong><\/td><td>7-year market exclusivity; tax credits; waived FDA fees; protocol assistance; priority review eligibility<\/td><\/tr><tr><td><strong>China-U.S. Parallel<\/strong><\/td><td>Dual IND approvals enable global development; China data supports U.S. registration<\/td><\/tr><tr><td><strong>Biomarker Strategy<\/strong><\/td><td>Companion diagnostic for TP53 Y220C mutation required; liquid biopsy potential for patient identification<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Approach<\/th><th>Product\/Platform<\/th><th>Developer<\/th><th>Status<\/th><th>GenSci128 Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>KRAS inhibitors<\/strong><\/td><td>Sotorasib, adagrasib<\/td><td>Amgen, Mirati\/BMS<\/td><td>Approved (G12C)<\/td><td>TP53 vs. KRAS target; different patient population<\/td><\/tr><tr><td><strong>Immunotherapy<\/strong><\/td><td>Pembrolizumab, nivolumab<\/td><td>Merck, BMS<\/td><td>Approved (MSI-H)<\/td><td>Direct tumor suppressor reactivation vs. immune modulation<\/td><\/tr><tr><td><strong>Other p53 approaches<\/strong><\/td><td>APR-246 (eprenetapopt), PC14586<\/td><td>Aprea, p53-Therapeutics<\/td><td>Phase II\/III<\/td><td>GenSci128 Y220C-specific vs. broad mutant p53; potentially better selectivity<\/td><\/tr><tr><td><strong>Changchun GeneScience<\/strong><\/td><td><strong>GenSci128<\/strong><\/td><td><strong>TP53 Y220C reactivator<\/strong><\/td><td><strong>Phase I-ready; ODD<\/strong><\/td><td><strong>First-in-class selective Y220C reactivator; oral convenience<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I<\/strong><\/td><td>2025-2027 (ongoing\/planned)<\/td><td>Safety, tolerability, MTD; pharmacokinetics; TP53 Y220C biomarker validation<\/td><\/tr><tr><td><strong>Phase II<\/strong><\/td><td>2027-2029<\/td><td>Efficacy signals in pancreatic, ovarian, breast, colorectal; expansion cohorts<\/td><\/tr><tr><td><strong>Regulatory Strategy<\/strong><\/td><td>2029-2030<\/td><td>Accelerated approval via ODD; Breakthrough Therapy designation pursuit; NDA\/MAA filings<\/td><\/tr><tr><td><strong>Companion Diagnostic<\/strong><\/td><td>2026-2028<\/td><td>TP53 Y220C mutation detection assay development and validation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, TP53 reactivation mechanism validation, and competitive positioning for GenSci128. Actual results may differ due to mutant p53 biology complexity, biomarker testing adoption, and competitive dynamics with other tumor suppressor-targeted therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Changchun GeneScience Pharmaceutical Inc. announced that GenSci128 tablets, its independently developed selective TP53 Y220C mutation&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,358],"class_list":["post-59343","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-genescience-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun GeneScience&#039;s GenSci128 Wins FDA Orphan Drug Designation \u2013 TP53 Y220C Reactivator Targets Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Changchun GeneScience Pharmaceutical Inc. announced that GenSci128 tablets, its independently developed selective TP53 Y220C mutation reactivator, has received U.S. FDA Orphan Drug Designation (ODD) for the treatment of pancreatic cancer. The Class 1 innovative chemical drug in China, which restores normal conformation and transcriptional activity of the mutant TP53 protein, holds IND approvals from both FDA and NMPA for locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation, including pancreatic, ovarian, breast, and colorectal cancers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59343\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun GeneScience&#039;s GenSci128 Wins FDA Orphan Drug Designation \u2013 TP53 Y220C Reactivator Targets Pancreatic Cancer\" \/>\n<meta property=\"og:description\" content=\"Changchun GeneScience Pharmaceutical Inc. announced that GenSci128 tablets, its independently developed selective TP53 Y220C mutation reactivator, has received U.S. FDA Orphan Drug Designation (ODD) for the treatment of pancreatic cancer. The Class 1 innovative chemical drug in China, which restores normal conformation and transcriptional activity of the mutant TP53 protein, holds IND approvals from both FDA and NMPA for locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation, including pancreatic, ovarian, breast, and colorectal cancers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59343\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-12T05:30:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-12T05:30:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59343#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59343\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun GeneScience&#8217;s GenSci128 Wins FDA Orphan Drug Designation \u2013 TP53 Y220C Reactivator Targets Pancreatic Cancer\",\"datePublished\":\"2026-03-12T05:30:54+00:00\",\"dateModified\":\"2026-03-12T05:30:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59343\"},\"wordCount\":562,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"GeneScience Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59343#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59343\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59343\",\"name\":\"Changchun GeneScience's GenSci128 Wins FDA Orphan Drug Designation \u2013 TP53 Y220C Reactivator Targets Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-12T05:30:54+00:00\",\"dateModified\":\"2026-03-12T05:30:55+00:00\",\"description\":\"Changchun GeneScience Pharmaceutical Inc. announced that GenSci128 tablets, its independently developed selective TP53 Y220C mutation reactivator, has received U.S. FDA Orphan Drug Designation (ODD) for the treatment of pancreatic cancer. The Class 1 innovative chemical drug in China, which restores normal conformation and transcriptional activity of the mutant TP53 protein, holds IND approvals from both FDA and NMPA for locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation, including pancreatic, ovarian, breast, and colorectal cancers.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59343#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59343\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59343#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun GeneScience&#8217;s GenSci128 Wins FDA Orphan Drug Designation \u2013 TP53 Y220C Reactivator Targets Pancreatic Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun GeneScience's GenSci128 Wins FDA Orphan Drug Designation \u2013 TP53 Y220C Reactivator Targets Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Changchun GeneScience Pharmaceutical Inc. announced that GenSci128 tablets, its independently developed selective TP53 Y220C mutation reactivator, has received U.S. FDA Orphan Drug Designation (ODD) for the treatment of pancreatic cancer. The Class 1 innovative chemical drug in China, which restores normal conformation and transcriptional activity of the mutant TP53 protein, holds IND approvals from both FDA and NMPA for locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation, including pancreatic, ovarian, breast, and colorectal cancers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59343","og_locale":"en_US","og_type":"article","og_title":"Changchun GeneScience's GenSci128 Wins FDA Orphan Drug Designation \u2013 TP53 Y220C Reactivator Targets Pancreatic Cancer","og_description":"Changchun GeneScience Pharmaceutical Inc. announced that GenSci128 tablets, its independently developed selective TP53 Y220C mutation reactivator, has received U.S. FDA Orphan Drug Designation (ODD) for the treatment of pancreatic cancer. The Class 1 innovative chemical drug in China, which restores normal conformation and transcriptional activity of the mutant TP53 protein, holds IND approvals from both FDA and NMPA for locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation, including pancreatic, ovarian, breast, and colorectal cancers.","og_url":"https:\/\/flcube.com\/?p=59343","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-12T05:30:54+00:00","article_modified_time":"2026-03-12T05:30:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59343#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59343"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun GeneScience&#8217;s GenSci128 Wins FDA Orphan Drug Designation \u2013 TP53 Y220C Reactivator Targets Pancreatic Cancer","datePublished":"2026-03-12T05:30:54+00:00","dateModified":"2026-03-12T05:30:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59343"},"wordCount":562,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","GeneScience Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59343#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59343","url":"https:\/\/flcube.com\/?p=59343","name":"Changchun GeneScience's GenSci128 Wins FDA Orphan Drug Designation \u2013 TP53 Y220C Reactivator Targets Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-12T05:30:54+00:00","dateModified":"2026-03-12T05:30:55+00:00","description":"Changchun GeneScience Pharmaceutical Inc. announced that GenSci128 tablets, its independently developed selective TP53 Y220C mutation reactivator, has received U.S. FDA Orphan Drug Designation (ODD) for the treatment of pancreatic cancer. The Class 1 innovative chemical drug in China, which restores normal conformation and transcriptional activity of the mutant TP53 protein, holds IND approvals from both FDA and NMPA for locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation, including pancreatic, ovarian, breast, and colorectal cancers.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59343#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59343"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59343#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun GeneScience&#8217;s GenSci128 Wins FDA Orphan Drug Designation \u2013 TP53 Y220C Reactivator Targets Pancreatic Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59343","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59343"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59343\/revisions"}],"predecessor-version":[{"id":59345,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59343\/revisions\/59345"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59343"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59343"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}